Antithrombotic Activity of DAB-15, a Novel Diazepinobenzimidazole Compound

• DOI: 10.1007/s10517-017-3675-4
• Publication Date: 2017-03-31T02:04:39Z
• Authors: A. A. Spasov; A. F. Kucheryavenko; V. S. Sirotenko; K. A. Gaidukova; A. S. Morkovnik; V. A. Anisimova; L. N. Divaeva; T. A. Kuz’menko
• Keywords: Ticlopidine; ED50

Antithrombotic activity of a new orally administered antiplatelet compound DAB-15 was compared to that of acetylsalicylic acid, ticlopidine, and clopidogrel in the experimental model of arterial thrombosis in rats caused by surface application of 50% ferric chloride (III) on the carotid artery. Compound DAB-15 exerted a dose-dependent antithrombotic effect and was superior to acetylsalicylic acid, ticlopidine and clopidogrel by 5, 7, and 4.9 times, respectively (by ED50). This necessitates studying of the action mechanism of this antiplatelet compound with consideration of its influence on different stages of the pathogenesis of platelet aggregation.